EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Inhibitory Fcγ receptor deletion enhances CD8 T cell stemness increasing anti-PD-1 therapy responsiveness against glioblastoma

Keun Bon Ku iD, Chae Won Kim iD, Yumin Kim iD, Byeong Hoon Kang iD, Jeongwoo La iD, In Kang, Won Hyung Park, Stephen Ahn, Sung Ki Lee, Heung Kyu Lee iD

Journal for ImmunoTherapy of Cancer · 2024

DOI: 10.1136/jitc-2024-009449 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von Keun Bon Ku und 9 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Republic of Korea. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Glioblastoma, Receptors, IgG. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research Foundation of Korea, Samsung Science and Technology Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Certain cancers present challenges for treatment because they are resistant to immune checkpoint blockade (ICB), attributed to low tumor mutational burden and the absence of T cell-inflamed features. Among these, glioblastoma (GBM) is notoriously resistant to ICB. To overcome this resistance, the identification of T cells with heightened stemness marked by T-cell factor 1 (TCF1) expression has gained attention. Several studies have explored ways to preserve stem-like T cells and prevent terminal exhaustion. In this study, we investigate a target that triggers stem-like properties in CD8 T cells to enhance the response to ICB in a murine GBM model.

Methods

Using Fcgr2b −/− mice and a murine GL261 GBM model, we confirmed the efficacy of anti-programmed cell death protein-1 (PD-1) immunotherapy, observing improved survival. Analysis of immune cells using fluorescence-activated cell sorting and single-cell RNA sequencing delineated distinct subsets of tumor-infiltrating CD8 T cells in Fcgr2b −/− mice. The crucial role of the stem-like feature in the response to anti-PD-1 treatment for reinvigorating CD8 T cells was analyzed. Adoptive transfer of OT-I cells into OVA-expressing GL261 models and CD8 T cell depletion in Fcgr2b −/− mice confirmed the significance of Fcgr2b −/− CD8 T cells in enhancing the antitumor response. Last, S1P 1 inhibitor treatment confirmed that the main source of tumor antigen-specific Fcgr2b −/− CD8 T cells is the tumor-draining lymph nodes (TdLNs).

Results

In a murine GBM model, anti-PD-1 monotherapy and single-Fc fragment of IgG receptor IIb (FcγRIIB) deletion exhibit limited efficacy. However, their combination substantially improves survival by enhancing cytotoxicity and proliferative capacity in tumor-infiltrating Fcgr2b −/− CD8 T cells. The improved response to anti-PD-1 treatment is associated with the tumor-specific memory T cells (Ttsms) exhibiting high stemness characteristics within the tumor microenvironment (TME). Ttsms in the TdLN thrives in a protective environment, maintaining stem-like characteristics and serving as a secure source for tumor infiltration. This underscores the significance of FcγRIIB ablation in triggering Ttsms and enhancing ICB therapy against GBM.

Conclusions

Deletion of FcγRIIB on CD8 T cells leads to the generation of a Ttsms, which is localized in TdLN and protected from the immunosuppressive TME. Incorporating these highly stemness-equipped Ttsms enhances the response to anti-PD-1 therapy in immune-suppressed brain tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD8-Positive T-LymphocytesGlioblastomaReceptors, IgGAnimalsMiceHumansImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorDisease Models, AnimalBrain NeoplasmsNeoplastic Stem Cells

Stichwörter der Autor:innen

Central Nervous System CancerImmune Checkpoint InhibitorT CellTumor Infiltrating Lymphocyte - TILTumor Microenvironment - TME

Substanzen

Receptors, IgGImmune Checkpoint InhibitorsProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Republic of Korea.
  • Center for Infectious Disease Vaccine and Diagnosis Innovation, Korea Research Institute of Chemical Technology, Daejeon 34114, Republic of Korea.
  • Laboratory of Host Defenses, Department of Biological Sciences, KAIST, Daejeon 34141, Republic of Korea.
  • Life Science Institute, KAIST, Daejeon 34141, Republic of Korea.
  • Department of Neurosurgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
  • Department of Obstetrics and Gynecology, College of Medicine, Myunggok Medical Research Center, Konyang University, Daejeon 35365, Republic of Korea.

ORCID-Profile: Keun Bon Ku, Chae Won Kim, Yumin Kim, Byeong Hoon Kang, Jeongwoo La, Heung Kyu Lee

Förderung

  • National Research Foundation of Korea
  • Samsung Science and Technology Foundation

Zitieren

APA

Ku, K. B., Kim, C. W., Kim, Y., Kang, B. H., La, J., Kang, I., Park, W. H., Ahn, S., Lee, S. K., & Lee, H. K. (2024). Inhibitory Fcγ receptor deletion enhances CD8 T cell stemness increasing anti-PD-1 therapy responsiveness against glioblastoma. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-009449

Vancouver

Ku KB, Kim CW, Kim Y, Kang BH, La J, Kang I, et al. Inhibitory Fcγ receptor deletion enhances CD8 T cell stemness increasing anti-PD-1 therapy responsiveness against glioblastoma. Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2024-009449

BibTeX
@article{Ku2024,
  author = {Ku, Keun Bon and Kim, Chae Won and Kim, Yumin and Kang, Byeong Hoon and La, Jeongwoo and Kang, In and Park, Won Hyung and Ahn, Stephen and Lee, Sung Ki and Lee, Heung Kyu},
  title = {Inhibitory Fcγ receptor deletion enhances CD8 T cell stemness increasing anti-PD-1 therapy responsiveness against glioblastoma},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2024},
  doi = {10.1136/jitc-2024-009449}
}
Kostenlos starten →